HERCULES, Calif.--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that in two studies published this month, ahead of peer-review, researchers in China reported that Bio-Rad’s QX200 Droplet Digital PCR (ddPCR) System showed superior sensitivity and precision for clinical detection of SARS-CoV-2 (the virus that causes COVID-19) compared to existing test methods that are performed using qPCR.
In the first study1, clinicians in Wuhan, China observed that a subset of infected individuals who tested negative for COVID-19 using qPCR tested positive using ddPCR. The findings suggest that ddPCR can reduce false negative results of COVID-19 without any increase to false positive results, and could be a powerful complement to the current standard of testing.
The second study2, led by the National Institute of Metrology and provincial CDCs in China, also concluded that Droplet Digital PCR significantly improves diagnostic detection accuracy of SARS-CoV-2 from 28.2% to 87.4%, thereby reducing false negatives. Furthermore, they found that Droplet Digital PCR is more sensitive and suitable for low virus load specimens from patients under isolation and observation even without any clinical symptoms.
“Bio-Rad is working to make ddPCR-based tests available for COVID-19 detection and is partnering with Biodesix in Colorado to bring an Emergency Use Authorization (EUA) test online,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “By more quickly identifying those who test positive for the virus, individuals can be quarantined and receive treatment as quickly as possible, helping to contain the spread of COVID-19.”
1https://www.medrxiv.org/content/10.1101/2020.02.29.20029439v1
2https://www.medrxiv.org/content/10.1101/2020.03.14.20036129v1
The referenced articles are preprints and have not been peer-reviewed. MedRxiv reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. Articles on MedRxiv have not been finalized by authors, might contain errors, and report information that has not yet been accepted or endorsed in any way by the scientific or medical community.
BIO-RAD, DROPLET DIGITAL PCR, and ddPCR, are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,100 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
